April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Effect of Intravitreal Triamcinolone in Advanced Coats Disease: Observations in Two Cases with Stages 4 and 5 Disease
Author Affiliations & Notes
  • Nicola G. Ghazi
    Vitreo/retinal, King Khaled Eye Specialist Hospital (KKESH), Riyadh, Saudi Arabia
  • Hanan Al Shamsi
    Vitreo/retinal, King Khaled Eye Specialist Hospital (KKESH), Riyadh, Saudi Arabia
  • Jorgen Larsson
    Vitreo/retinal, King Khaled Eye Specialist Hospital (KKESH), Riyadh, Saudi Arabia
  • Footnotes
    Commercial Relationships  Nicola G. Ghazi, None; Hanan Al Shamsi, None; Jorgen Larsson, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 6155. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nicola G. Ghazi, Hanan Al Shamsi, Jorgen Larsson; Effect of Intravitreal Triamcinolone in Advanced Coats Disease: Observations in Two Cases with Stages 4 and 5 Disease. Invest. Ophthalmol. Vis. Sci. 2011;52(14):6155.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To report our experience with intravitreal triamcinolone (IVTA) in cases of advanced Coats disease with massive subretinal exudation (MSRE)

Methods: : Two eyes of two cases of advanced Coats disease, one eye with stage 4 disease and one with stage 5, received IVTA. One eye received 1mg and one received 4mg IVTA. Because of the age and the limited space between the lens and the remaining vitreous cavity, the injections were performed under general anesthesia with ultrasound guidance.

Results: : Both eyes had MSRE with total bullous retinal detachment that was almost touching the crystalline lens. One eye had neovascular glaucoma. IVTA was associated with almost total resolution of the subretinal fluid within 4 weeks from the injection. Subsequent application of ablative therapy without the need for surgical drainage was successfully performed on both eyes. None of the patients developed side effects from the treatment.

Conclusions: : Our findings suggest that IVTA may be an effective alternative to surgical drainage in advanced cases of Coats disease. To our knowledge, 1mg of IVTA has not been previously reported in this setting. Larger prospective studies to address the dose, safety and efficacy of IVTA in the management of advanced Coats disease are needed.

Keywords: retinal detachment • retina • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×